<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7136885/results/search/disease/results.xml">
  <result pre="Today1359-64461878-5832Published by Elsevier Ltd. pmcid: 7136885S1359-6446(20)30117-3 doi: 10.1016/j.drudis.2020.03.010 : Article" exact="Viral" post="replicons as valuable tools for drug discovery HannemannHolgerhhannemann@thenativeantigencompany.com[], pmc-release:"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="resource centre remains active. Highlights •Viral replicons are self-amplifying, subgenomic" exact="viral" post="RNAs that cannot form infectious particles. •Safety of viral"/>
  <result pre="•Viral replicons are self-amplifying, subgenomic viral RNAs that cannot form" exact="infectious" post="particles. •Safety of viral replicons has made them a"/>
  <result pre="subgenomic viral RNAs that cannot form infectious particles. •Safety of" exact="viral" post="replicons has made them a popular tool for antiviral"/>
  <result pre="RNA viruses can cause severe diseases such as dengue, Lassa," exact="chikungunya" post="and Ebola. Many of these viruses can only be"/>
  <result pre="sufficient for their own replication but which do not produce" exact="infectious" post="virions. Replicons can persist in cells and are passed"/>
  <result pre="efficient and high-throughput testing of drug candidates that act on" exact="viral" post="transcription, translation and replication. This review will explore the"/>
  <result pre="will explore the history and potential for drug discovery of" exact="hepatitis" post="C virus, dengue virus, respiratory syncytial virus, Ebola virus"/>
  <result pre="potential for drug discovery of hepatitis C virus, dengue virus," exact="respiratory" post="syncytial virus, Ebola virus and norovirus replicon and minigenome"/>
  <result pre="Vaccines and therapeutics are the main weapons deployed to combat" exact="infectious diseases." post="Vaccines have been successful in dramatically lowering infection rates"/>
  <result pre="combat infectious diseases. Vaccines have been successful in dramatically lowering" exact="infection" post="rates for diseases like measles, mumps, rubella, diphtheria, pertussis"/>
  <result pre="lowering infection rates for diseases like measles, mumps, rubella, diphtheria," exact="pertussis" post="and many more, and have led to the complete"/>
  <result pre="diphtheria, pertussis and many more, and have led to the" exact="complete" post="eradication of smallpox and near-eradication of polio 1, 2,"/>
  <result pre="many more, and have led to the complete eradication of" exact="smallpox" post="and near-eradication of polio 1, 2, 3, 4. However,"/>
  <result pre="led to the complete eradication of smallpox and near-eradication of" exact="polio" post="1, 2, 3, 4. However, safe and effective vaccines"/>
  <result pre="the development of effective drug treatments for patients suffering from" exact="infectious diseases" post="is imperative [8]. However, drug lead discovery and optimisation"/>
  <result pre="is imperative [8]. However, drug lead discovery and optimisation for" exact="infectious" post="agents can be technically challenging for a variety of"/>
  <result pre="researchers and institutions. The 2018 WHO Blueprint List of Priority" exact="Diseases" post="is exclusively populated by RNA viruses that fulfil one,"/>
  <result pre="a necessity. Small-compound drugs act on proteins involved in the" exact="viral" post="life cycle: entry into host cells, virus uncoating, replication"/>
  <result pre="into host cells, virus uncoating, replication and translation of the" exact="viral" post="genome or suppression of the innate host immune response."/>
  <result pre="suppression of the innate host immune response. The development of" exact="viral" post="pseudotypes and virus-like particles (VLPs) has made research and"/>
  <result pre="15. By contrast, analysis of subgenomic replicons enables uncoupling of" exact="viral" post="replication, transcription and translation from virus assembly, host cell"/>
  <result pre="broadly defined as autonomously replicating DNA or RNA molecules, whereas" exact="viral" post="subgenomic replicons are usually produced by deletion of one"/>
  <result pre="reverse genetics: a process of storage and manipulation of entire" exact="viral" post="genomes hosted on plasmids, and the recreation of viral"/>
  <result pre="entire viral genomes hosted on plasmids, and the recreation of" exact="viral" post="RNA genomes by in vitro or in vivo transcription"/>
  <result pre="during cell division, minigenomes based on plasmid transfection have a" exact="limited" post="lifespan and need to be recreated before experimentation. Although"/>
  <result pre="the replicon-harbouring cell pool owing to generally poor fidelity of" exact="viral" post="RNA-dependent RNA polymerases (RdRp). Table 1 Replicon and minigenome"/>
  <result pre="relevant viruses Table 1 Virus family Replicon Minigenome Refs Flaviviridae" exact="Dengue" post="virus (DENV) [45] Positive-sense single-stranded RNA viruses West Nile"/>
  <result pre="West Nile virus (WNV) [41] Kunjin virus (KUNV) [17] Tick-borne" exact="encephalitis" post="virus (TBEV) [105] Yellow fever virus (YFV) [42] Japanese"/>
  <result pre="[41] Kunjin virus (KUNV) [17] Tick-borne encephalitis virus (TBEV) [105]" exact="Yellow fever" post="virus (YFV) [42] Japanese encephalitis virus (JEV) [106] Hepatitis"/>
  <result pre="Tick-borne encephalitis virus (TBEV) [105] Yellow fever virus (YFV) [42]" exact="Japanese encephalitis" post="virus (JEV) [106] Hepatitis C virus (HCV) [18] Bovine"/>
  <result pre="encephalitis virus (TBEV) [105] Yellow fever virus (YFV) [42] Japanese" exact="encephalitis" post="virus (JEV) [106] Hepatitis C virus (HCV) [18] Bovine"/>
  <result pre="Yellow fever virus (YFV) [42] Japanese encephalitis virus (JEV) [106]" exact="Hepatitis" post="C virus (HCV) [18] Bovine viral diarrhoea virus (BVDB)"/>
  <result pre="Japanese encephalitis virus (JEV) [106] Hepatitis C virus (HCV) [18]" exact="Bovine" post="viral diarrhoea virus (BVDB) [107] Togaviridae Sindbis virus (SINV)"/>
  <result pre="encephalitis virus (JEV) [106] Hepatitis C virus (HCV) [18] Bovine" exact="viral" post="diarrhoea virus (BVDB) [107] Togaviridae Sindbis virus (SINV) [58]"/>
  <result pre="[107] Togaviridae Sindbis virus (SINV) [58] Chikungunya virus (CHIKV) [61]" exact="Venezuelan equine encephalitis" post="virus (VEEV) [19] Western equine encephalitis virus (WEEV) [67]"/>
  <result pre="Sindbis virus (SINV) [58] Chikungunya virus (CHIKV) [61] Venezuelan equine" exact="encephalitis" post="virus (VEEV) [19] Western equine encephalitis virus (WEEV) [67]"/>
  <result pre="Chikungunya virus (CHIKV) [61] Venezuelan equine encephalitis virus (VEEV) [19]" exact="Western equine encephalitis" post="virus (WEEV) [67] Semliki forest virus (SFV) [108] Coronaviridae"/>
  <result pre="(CHIKV) [61] Venezuelan equine encephalitis virus (VEEV) [19] Western equine" exact="encephalitis" post="virus (WEEV) [67] Semliki forest virus (SFV) [108] Coronaviridae"/>
  <result pre="encephalitis virus (WEEV) [67] Semliki forest virus (SFV) [108] Coronaviridae" exact="Severe" post="acute respiratory syndrome (SARS) virus [22] Middle eastern respiratory"/>
  <result pre="virus (WEEV) [67] Semliki forest virus (SFV) [108] Coronaviridae Severe" exact="acute" post="respiratory syndrome (SARS) virus [22] Middle eastern respiratory syndrome"/>
  <result pre="(WEEV) [67] Semliki forest virus (SFV) [108] Coronaviridae Severe acute" exact="respiratory" post="syndrome (SARS) virus [22] Middle eastern respiratory syndrome (MERS)"/>
  <result pre="[67] Semliki forest virus (SFV) [108] Coronaviridae Severe acute respiratory" exact="syndrome" post="(SARS) virus [22] Middle eastern respiratory syndrome (MERS) virus"/>
  <result pre="Coronaviridae Severe acute respiratory syndrome (SARS) virus [22] Middle eastern" exact="respiratory" post="syndrome (MERS) virus [109] Caliciviridae Human norovirus (NOV) [92]"/>
  <result pre="Severe acute respiratory syndrome (SARS) virus [22] Middle eastern respiratory" exact="syndrome" post="(MERS) virus [109] Caliciviridae Human norovirus (NOV) [92] Hepeviridae"/>
  <result pre="syndrome (MERS) virus [109] Caliciviridae Human norovirus (NOV) [92] Hepeviridae" exact="Hepatitis" post="E virus [20] Picornaviridae Polio virus [16] Foot-and-mouth disease"/>
  <result pre="Human norovirus (NOV) [92] Hepeviridae Hepatitis E virus [20] Picornaviridae" exact="Polio" post="virus [16] Foot-and-mouth disease virus (FMDV) [119] Enterovirus 71"/>
  <result pre="Hepeviridae Hepatitis E virus [20] Picornaviridae Polio virus [16] Foot-and-mouth" exact="disease" post="virus (FMDV) [119] Enterovirus 71 (EV71) [21] Astroviridae Human"/>
  <result pre="71 (EV71) [21] Astroviridae Human astrovirus [120] Mononegavirales Rhabdoviridae Vesicular" exact="stomatitis" post="virus (VSV) Vesicular stomatitis virus (VSV) 115, 116 Paramyxoviridae"/>
  <result pre="Human astrovirus [120] Mononegavirales Rhabdoviridae Vesicular stomatitis virus (VSV) Vesicular" exact="stomatitis" post="virus (VSV) 115, 116 Paramyxoviridae Nipah virus [113] Human"/>
  <result pre="115, 116 Paramyxoviridae Nipah virus [113] Human metapneumovirus (HMPV) [114]" exact="Respiratory" post="syncytial virus (RSV) Respiratory syncytial virus (RSV) 76, 78"/>
  <result pre="virus [113] Human metapneumovirus (HMPV) [114] Respiratory syncytial virus (RSV)" exact="Respiratory" post="syncytial virus (RSV) 76, 78 Filoviridae Ebola virus (EBOV)"/>
  <result pre="Ebola virus (EBOV) [99] Marburg virus (MARV) [117] Bunyavirales Phenuiviridae" exact="Rift Valley fever" post="virus (RVFV) [110] Severe fever with thrombocytopenia virus (STFSV)"/>
  <result pre="(MARV) [117] Bunyavirales Phenuiviridae Rift Valley fever virus (RVFV) [110]" exact="Severe" post="fever with thrombocytopenia virus (STFSV) [111] Hantaviridae Hantaan virus"/>
  <result pre="Phenuiviridae Rift Valley fever virus (RVFV) [110] Severe fever with" exact="thrombocytopenia" post="virus (STFSV) [111] Hantaviridae Hantaan virus [118] Arenaviridae Lassa"/>
  <result pre="use of subgenomic replicons in the development of drugs against" exact="hepatitis" post="C virus (HCV) and then illustrate the potential of"/>
  <result pre="(HCV) and then illustrate the potential of dengue virus, togavirus," exact="respiratory" post="syncytial virus and norovirus replicons, and the Ebola virus"/>
  <result pre="recent years replicons have been derived from viruses such as" exact="hepatitis" post="E virus, enterovirus 71, severe acute respiratory syndrome virus,"/>
  <result pre="from viruses such as hepatitis E virus, enterovirus 71, severe" exact="acute" post="respiratory syndrome virus, among others, but their description is"/>
  <result pre="viruses such as hepatitis E virus, enterovirus 71, severe acute" exact="respiratory" post="syndrome virus, among others, but their description is beyond"/>
  <result pre="such as hepatitis E virus, enterovirus 71, severe acute respiratory" exact="syndrome" post="virus, among others, but their description is beyond the"/>
  <result pre="globally [23]. Infected individuals have a 75–85% likelihood of developing" exact="chronic" post="infection, which when left untreated can lead to liver"/>
  <result pre="developing chronic infection, which when left untreated can lead to" exact="liver cirrhosis" post="and hepatocarcinoma [24]. Previous to 2011 [when the first"/>
  <result pre="chronic infection, which when left untreated can lead to liver" exact="cirrhosis" post="and hepatocarcinoma [24]. Previous to 2011 [when the first"/>
  <result pre="weeks after completion of antiviral therapy of 40–80%, depending on" exact="viral" post="genotype [25]. HCV is a hepacivirus within the Flaviviridae"/>
  <result pre="genome encodes a polyprotein that is proteolytically cleaved by the" exact="viral" post="NS3/4A and cellular proteases into the three structural proteins:"/>
  <result pre="NS5A and NS5B. Most HCV strains will not establish productive" exact="infection" post="in cell culture and it was not until 2005"/>
  <result pre="development of second-generation DAAs such as ledipasvir, acting on the" exact="viral" post="NS5A regulatory protein, and sofosbuvir, a nucleotide phosphoramidate prodrug"/>
  <result pre="HCV by DAA combination therapy. Figure 1 Graphic representation of" exact="viral" post="genomes and their derived replicons and minigenomes. Each region"/>
  <result pre="nonviral protein. Internal ribosome entry sites (IRES) and the foot-and-mouth" exact="disease" post="virus 2A autoprotease sequences (FMDV2A) are marked by lines"/>
  <result pre="lines or arrows, respectively. For minigenomes (d,f) plasmid-driven expression of" exact="viral" post="genes is shown by circularized lines. (a) Hepatitis C"/>
  <result pre="expression of viral genes is shown by circularized lines. (a)" exact="Hepatitis" post="C virus (HCV) genome (ai) and its derived replicon"/>
  <result pre="Translation of NS3–NS5B was driven by an IRES sequence. (b)" exact="Dengue" post="virus (DENV) genome (bi) and its derived replicons (bii"/>
  <result pre="established by replacement of the structural polyprotein with pac. (d)" exact="Respiratory" post="syncytial virus genome (di) and its derived minigenome system"/>
  <result pre="the 5′ leader and the 3′ trailer sequences of the" exact="viral" post="genome and plasmid-driven co-expression of the viral polymerase (L),"/>
  <result pre="sequences of the viral genome and plasmid-driven co-expression of the" exact="viral" post="polymerase (L), nucleoprotein (N), phosphoprotein (P) and matrix protein"/>
  <result pre="replicon was established by replacement of the majority of the" exact="viral" post="protein (VP)1 coding region with neo. (f) Ebola virus"/>
  <result pre="(+) sense 5′ leader and 3′ trailer sequences of the" exact="viral" post="genome and plasmid-driven co-expression of the viral polymerase (L),"/>
  <result pre="sequences of the viral genome and plasmid-driven co-expression of the" exact="viral" post="polymerase (L), VP30, VP35 and the nucleoprotein (NP). Dengue"/>
  <result pre="the viral polymerase (L), VP30, VP35 and the nucleoprotein (NP)." exact="Dengue" post="virus replicons Dengue serotype 1–4 viruses (DENV1–4) are arthropod-borne"/>
  <result pre="(L), VP30, VP35 and the nucleoprotein (NP). Dengue virus replicons" exact="Dengue" post="serotype 1–4 viruses (DENV1–4) are arthropod-borne flaviviruses spread by"/>
  <result pre="with dengue virus every year. Despite a high proportion of" exact="infections" post="being asymptomatic, 96 million cases of dengue disease are"/>
  <result pre="high proportion of infections being asymptomatic, 96 million cases of" exact="dengue disease" post="are diagnosed annually. Roughly 5% of symptomatic patients progress"/>
  <result pre="proportion of infections being asymptomatic, 96 million cases of dengue" exact="disease" post="are diagnosed annually. Roughly 5% of symptomatic patients progress"/>
  <result pre="cases of dengue disease are diagnosed annually. Roughly 5% of" exact="symptomatic" post="patients progress to dengue haemorrhagic fever and/or dengue shock"/>
  <result pre="5% of symptomatic patients progress to dengue haemorrhagic fever and/or" exact="dengue shock syndrome," post="which require hospitalisation and can be fatal. To date,"/>
  <result pre="no approved specific drug treatment available against dengue virus [38]." exact="Dengue" post="virus has a single-stranded, positive-sense RNA genome with a"/>
  <result pre="amino acid polyprotein. The polyprotein is then processed by the" exact="viral" post="NS2b/3 and cellular proteases into the three structural proteins"/>
  <result pre="established for closely related viruses like Kunjin, West Nile and" exact="yellow fever" post="virus 17, 41, 42. In 2011, selectable DENV replicons"/>
  <result pre="sequence, and translation of the reporter was driven by the" exact="viral" post="5′ UTR. The reporter is separated from the antibiotic"/>
  <result pre="reporter is separated from the antibiotic resistance by the foot-and-mouth" exact="disease" post="virus (FMDV) 2A autoprotease, enabling post-translational cleavage of the"/>
  <result pre="from the resistance marker 43, 44, 45, 46 (Fig. 1b)." exact="Dengue" post="replicon systems have been successfully used for hit discovery"/>
  <result pre="is essential for replication, and is known to interact with" exact="viral" post="and cellular proteins to form the dengue replication complex"/>
  <result pre="such as hirsutine, using the dengue subgenomic replicon system [52]." exact="Dengue" post="virus drug discovery is a hotbed of activity as"/>
  <result pre="the clinic. Togavirus replicons Chikungunya virus (CHIKV), western, eastern and" exact="Venezuelan equine encephalitis" post="virus (WEEV, EEEV, VEEV) and Sindbis virus (SINV) are"/>
  <result pre="Togavirus replicons Chikungunya virus (CHIKV), western, eastern and Venezuelan equine" exact="encephalitis" post="virus (WEEV, EEEV, VEEV) and Sindbis virus (SINV) are"/>
  <result pre="can cause symptoms such as fever, rash and joint and" exact="muscle" post="pain [54]. VEEV is confined to Central and South"/>
  <result pre="and joint and muscle pain [54]. VEEV is confined to" exact="Central" post="and South America and can infect humans causing flu-like"/>
  <result pre="by translation of a 26S subgenomic RNA produced by the" exact="viral" post="RdRp from a promoter located between the two coding"/>
  <result pre="of the SINV and CHIKV old world togaviruses, using wildtype" exact="viral" post="sequences, caused cytopathic effect in host cells, and could"/>
  <result pre="to assess safety and efficacy of ivermectin use in DENV" exact="infections" post="[65]. In a follow-up study, berberine was shown to"/>
  <result pre="was shown to inhibit the MAP kinase pathway activated by" exact="CHIKV infection," post="showing that it was effective in alleviating symptoms of"/>
  <result pre="infection, showing that it was effective in alleviating symptoms of" exact="CHIKV infection" post="in a mouse model [66]. However, no clinical studies"/>
  <result pre="showing that it was effective in alleviating symptoms of CHIKV" exact="infection" post="in a mouse model [66]. However, no clinical studies"/>
  <result pre="2206 extracts of marine organisms from diverse geographic regions. Thirty-seven" exact="primary" post="hits were identified and, from these primary hits, an"/>
  <result pre="geographic regions. Thirty-seven primary hits were identified and, from these" exact="primary" post="hits, an antimycin A derivative from the marine actinomycete"/>
  <result pre="recombinant proteins and as vaccine platforms 68, 69, 70, 71." exact="Respiratory" post="syncytial virus (RSV) replicon and minigenome RSV is a"/>
  <result pre="(RSV) replicon and minigenome RSV is a common cause of" exact="acute" post="lower respiratory infections. In 2015 an estimated 33 million"/>
  <result pre="replicon and minigenome RSV is a common cause of acute" exact="lower" post="respiratory infections. In 2015 an estimated 33 million cases"/>
  <result pre="and minigenome RSV is a common cause of acute lower" exact="respiratory" post="infections. In 2015 an estimated 33 million cases were"/>
  <result pre="small-molecule broadband antiviral, and palivizumab, a monoclonal antibody targeting the" exact="viral" post="fusion protein, have been approved for treatment and prevention"/>
  <result pre="blasticidin S deaminase (bla). The replicon was found to be" exact="stable" post="and non-cytopathic in several cell lines. It could be"/>
  <result pre="F in trans, and transferred to different cell lines by" exact="infection" post="with resulting trans-packaged VLPs (Fig. 1d) [78]. This replicon"/>
  <result pre="an outbreak of ‘winter vomiting disease’ in Norwalk, Ohio. The" exact="disease" post="manifests in self-limiting fulminant vomiting, diarrhoea and low-grade fever"/>
  <result pre="world [85]. Despite very high virus titers in stools during" exact="infection" post="and successful culture of murine noroviruses in RAW264.7 and"/>
  <result pre="infection and successful culture of murine noroviruses in RAW264.7 and" exact="primary" post="murine cells, human noroviruses have eluded efficient propagation in"/>
  <result pre="six nonstructural proteins NS6 (protease), NS7 (RdRp), NS5/VPg (capping of" exact="viral" post="RNA), NS3 (RNA helicase) and NS1/2 and NS4, which"/>
  <result pre="proteins VP1 and VP2, respectively (reviewed in Ref. [88]). The" exact="short" post="5′ and 3′ UTRs flanking the ORFs contain secondary"/>
  <result pre="The short 5′ and 3′ UTRs flanking the ORFs contain" exact="secondary" post="structures that stretch into the coding regions and are"/>
  <result pre="replication, transcription and pathogenesis 89, 90. In 2004, the plasmid-based" exact="infectious" post="clone NV FL101 (based on the 1968 Norwalk strain)"/>
  <result pre="norovirus replicon [95]. However, owing to the fact that norovirus" exact="infections" post="are short-lived and self-limiting, the interest of pharma companies"/>
  <result pre="vaccines and therapeutics against Ebola and related filoviruses. EBOV causes" exact="viral" post="haemorrhagic fever with mortality rates of up to 80%,"/>
  <result pre="is ∼19 knt in size and codes for eight major" exact="viral" post="proteins: Nucleoprotein (NP), glycoprotein (GP) and soluble glycoprotein (sGP),"/>
  <result pre="that is co-expressed with the reporter for creation of a" exact="stable" post="cell line continuously replicating the minigenome and T7-polymerase-driven expression"/>
  <result pre="remarks The advent of reverse genetics and the establishment of" exact="stable" post="replicon-harbouring cell lines and minigenomes have furthered our understanding"/>
  <result pre="and facilitated the advancement of antiviral drug discovery in the" exact="absence of" post="viable cell culture systems and for viruses that require"/>
  <result pre="untargeted infections: a retrospective cohort studyHum. Vaccines Immunother.13201718791883 2SchwartzK.L.Effectiveness of" exact="pertussis" post="vaccination and duration of immunityCan. Med. Assoc. J.1882016E39940627672225 3NathansonN.Eradication"/>
  <result pre="vaccination and duration of immunityCan. Med. Assoc. J.1882016E39940627672225 3NathansonN.Eradication of" exact="poliomyelitis" post="in the United StatesRev. Infect. Dis.419829409507146731 4StrassburgM.A.The global eradication"/>
  <result pre="List of Priority Diseases. Available at: https://globalbiodefense.com/2018/02/12/who-updates-blueprint-list-of-priority-diseases/. 13BasuA.High-throughput screening of" exact="viral" post="entry inhibitors using pseudotyped virusCurr. Protoc. Pharmacol.132010B.3 14SalataC.Ebola virus"/>
  <result pre="the flavivirus Kunjin: construction and applicationsJ. Virol.711997149715058995675 18LohmannV.Replication of subgenomic" exact="hepatitis" post="C virus RNAs in a hepatoma cell lineScience285199911011310390360 19PushkoP.Replicon-helper"/>
  <result pre="RNAs in a hepatoma cell lineScience285199911011310390360 19PushkoP.Replicon-helper systems from attenuated" exact="Venezuelan equine encephalitis" post="virus: expression of heterologous genes in vitro and immunization"/>
  <result pre="a hepatoma cell lineScience285199911011310390360 19PushkoP.Replicon-helper systems from attenuated Venezuelan equine" exact="encephalitis" post="virus: expression of heterologous genes in vitro and immunization"/>
  <result pre="immunization against heterologous pathogens in vivoVirology23919973894019434729 20EmersonS.U.In vitro replication of" exact="hepatitis" post="E virus (HEV) genomes and of an HEV replicon"/>
  <result pre="a selectable replicon RNAJ. Gen. Virol.8520041717172515166457 23Mohd HanafiahK.Global epidemiology of" exact="hepatitis" post="C virus infection: new estimates of age-specific antibody to"/>
  <result pre="25European Association for Study of LiverEASL recommendations on treatment of" exact="hepatitis" post="C 2015J. Hepatol.63201519923625911336 26WakitaT.Production of infectious hepatitis C virus"/>
  <result pre="recommendations on treatment of hepatitis C 2015J. Hepatol.63201519923625911336 26WakitaT.Production of" exact="infectious" post="hepatitis C virus in tissue culture from a cloned"/>
  <result pre="on treatment of hepatitis C 2015J. Hepatol.63201519923625911336 26WakitaT.Production of infectious" exact="hepatitis" post="C virus in tissue culture from a cloned viral"/>
  <result pre="infectious hepatitis C virus in tissue culture from a cloned" exact="viral" post="genomeNat. Med.11200579179615951748 27LindenbachB.D.Complete replication of hepatitis C virus in"/>
  <result pre="culture from a cloned viral genomeNat. Med.11200579179615951748 27LindenbachB.D.Complete replication of" exact="hepatitis" post="C virus in cell cultureScience309200562362615947137 28VenkatramanS.Discovery of boceprevir, a"/>
  <result pre="of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of" exact="chronic hepatitis" post="C infectionsTrends Pharmacol. Sci.33201228929422521415 29KwongA.D.Discovery and development of telaprevir:"/>
  <result pre="boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic" exact="hepatitis" post="C infectionsTrends Pharmacol. Sci.33201228929422521415 29KwongA.D.Discovery and development of telaprevir:"/>
  <result pre="of telaprevir: an NS3-4A protease inhibitor for treating genotype 1" exact="chronic hepatitis" post="C virusNat. Biotechnol.292011993100322068541 30BlightK.J.Efficient replication of hepatitis C virus"/>
  <result pre="telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic" exact="hepatitis" post="C virusNat. Biotechnol.292011993100322068541 30BlightK.J.Efficient replication of hepatitis C virus"/>
  <result pre="genotype 1 chronic hepatitis C virusNat. Biotechnol.292011993100322068541 30BlightK.J.Efficient replication of" exact="hepatitis" post="C virus genotype 1a RNAs in cell cultureJ. Virol.7720033181319012584342"/>
  <result pre="Virol.7720033181319012584342 31IkedaM.Selectable subgenomic and genome-length dicistronic RNAs derived from an" exact="infectious" post="molecular clone of the HCV-N strain of hepatitis C"/>
  <result pre="from an infectious molecular clone of the HCV-N strain of" exact="hepatitis" post="C virus replicate efficiently in cultured Huh7 cellsJ. Virol.7620022997300611861865"/>
  <result pre="cultured Huh7 cellsJ. Virol.7620022997300611861865 32KatoT.Efficient replication of the genotype 2a" exact="hepatitis" post="C virus subgenomic repliconGastroenterology12520031808181714724833 33SaeedM.Efficient replication of genotype 3a"/>
  <result pre="virus subgenomic repliconGastroenterology12520031808181714724833 33SaeedM.Efficient replication of genotype 3a and 4a" exact="hepatitis" post="C virus replicons in human hepatoma cellsAntimicrob. Agents Chemother.5620125365537322869572"/>
  <result pre="Agents Chemother.5820145386539424982066 35YuM.Robust and persistent replication of the genotype 6a" exact="hepatitis" post="C virus replicon in cell cultureAntimicrob. Agents Chemother.5820142638264624550344 36LinkJ.O.Discovery"/>
  <result pre="a potent, once-daily oral NS5A inhibitor for the treatment of" exact="hepatitis" post="C virus infectionJ. Med. Chem.5720142033204624320933 37GentileI.The discovery of sofosbuvir:"/>
  <result pre="Chem.5720142033204624320933 37GentileI.The discovery of sofosbuvir: a revolution for therapy of" exact="chronic hepatitis" post="CExpert Opin. Drug Discov.1020151363137726563720 38World Health Organization. Dengue and"/>
  <result pre="37GentileI.The discovery of sofosbuvir: a revolution for therapy of chronic" exact="hepatitis" post="CExpert Opin. Drug Discov.1020151363137726563720 38World Health Organization. Dengue and"/>
  <result pre="of chronic hepatitis CExpert Opin. Drug Discov.1020151363137726563720 38World Health Organization." exact="Dengue" post="and severe dengue fact sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. 39NgW.C.The"/>
  <result pre="hepatitis CExpert Opin. Drug Discov.1020151363137726563720 38World Health Organization. Dengue and" exact="severe dengue" post="fact sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. 39NgW.C.The 5’ and 3’"/>
  <result pre="untranslated regions of the flaviviral genomeViruses9201710.3390/v9060137 40PangX.Development of dengue virus" exact="type 2" post="replicons capable of prolonged expression in host cellsBMC Microbiol.120011811580862"/>
  <result pre="York strain of West Nile virusVirology296200221923312069521 42JonesC.T.Construction and applications of" exact="yellow fever" post="virus repliconsVirology331200524725915629769 43LeardkamolkarnV.Development of dengue type-2 virus replicons expressing"/>
  <result pre="type-2 virus replicons expressing GFP reporter gene in study of" exact="viral" post="RNA replicationVirus Res.163201255256222197424 44ManzanoM.Identification of cis-acting elements in the"/>
  <result pre="cis-acting elements in the 3’-untranslated region of the dengue virus" exact="type 2" post="RNA that modulate translation and replicationJ. Biol. Chem.2862011225212253421515677 45NgC.Y.Construction"/>
  <result pre="translation and replicationJ. Biol. Chem.2862011225212253421515677 45NgC.Y.Construction and characterization of a" exact="stable" post="subgenomic dengue virus type 2 replicon system for antiviral"/>
  <result pre="Chem.2862011225212253421515677 45NgC.Y.Construction and characterization of a stable subgenomic dengue virus" exact="type 2" post="replicon system for antiviral compound and siRNA testingAntiviral Res.76200722223117662475"/>
  <result pre="replicon system for antiviral compound and siRNA testingAntiviral Res.76200722223117662475 46RyanM.D.DrewJ.Foot-and-mouth" exact="disease" post="virus 2A oligopeptide mediated cleavage of an artificial polyproteinEMBO"/>
  <result pre="molecule libraryAntiviral Res.147201714915829037976 50ZmurkoJ.Flaviviral NS4b, chameleon and jack-in-the-box roles in" exact="viral" post="replication and pathogenesis, and a molecular target for antiviral"/>
  <result pre="mutations in a Sindbis virus variant able to establish persistent" exact="infection" post="in BHK cells: the importance of a mutation in"/>
  <result pre="Virol.7319993854386510196280 61PohjalaL.Inhibitors of alphavirus entry and replication identified with a" exact="stable" post="Chikungunya replicon cell line and virus-based assaysPLoS One62011e28923 62TammK.Mutations"/>
  <result pre="cytotoxicity of Semliki Forest virusJ. Gen. Virol.89200867668618272758 63PetrakovaO.Noncytopathic replication of" exact="Venezuelan equine encephalitis" post="virus and eastern equine encephalitis virus replicons in mammalian"/>
  <result pre="Semliki Forest virusJ. Gen. Virol.89200867668618272758 63PetrakovaO.Noncytopathic replication of Venezuelan equine" exact="encephalitis" post="virus and eastern equine encephalitis virus replicons in mammalian"/>
  <result pre="Gen. Virol.89200867668618272758 63PetrakovaO.Noncytopathic replication of Venezuelan equine encephalitis virus and" exact="eastern equine encephalitis" post="virus replicons in mammalian cellsJ. Virol.7920057597760815919912 64VargheseF.S.Discovery of berberine,"/>
  <result pre="63PetrakovaO.Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine" exact="encephalitis" post="virus replicons in mammalian cellsJ. Virol.7920057597760815919912 64VargheseF.S.Discovery of berberine,"/>
  <result pre="Virol.7920057597760815919912 64VargheseF.S.Discovery of berberine, abamectin and ivermectin as antivirals against" exact="chikungunya" post="and other alphavirusesAntiviral Res.126201611712426752081 65Efficacy and Safety of Ivermectin"/>
  <result pre="and other alphavirusesAntiviral Res.126201611712426752081 65Efficacy and Safety of Ivermectin Against" exact="Dengue" post="Infection. Available at: https://clinicaltrials.gov/ct2/show/NCT02045069. 66VargheseF.S.The antiviral alkaloid berberine reduces"/>
  <result pre="of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative" exact="adult" post="volunteersVaccine28200948449319857446 71WeckerM.Phase I safety and immunogenicity evaluations of an"/>
  <result pre="in healthy HIV-1-uninfected adultsClin. Vaccine Immunol.1920121651166022914365 72ShiT.Global, regional, and national" exact="disease" post="burden estimates of acute lower respiratory infections due to"/>
  <result pre="Vaccine Immunol.1920121651166022914365 72ShiT.Global, regional, and national disease burden estimates of" exact="acute" post="lower respiratory infections due to respiratory syncytial virus in"/>
  <result pre="Immunol.1920121651166022914365 72ShiT.Global, regional, and national disease burden estimates of acute" exact="lower" post="respiratory infections due to respiratory syncytial virus in young"/>
  <result pre="72ShiT.Global, regional, and national disease burden estimates of acute lower" exact="respiratory" post="infections due to respiratory syncytial virus in young children"/>
  <result pre="regional, and national disease burden estimates of acute lower respiratory" exact="infections" post="due to respiratory syncytial virus in young children in"/>
  <result pre="disease burden estimates of acute lower respiratory infections due to" exact="respiratory" post="syncytial virus in young children in 2015: a systematic"/>
  <result pre="2015: a systematic review and modelling studyLancet390201794695828689664 73KimH.W.Respiratory syncytial virus" exact="disease" post="in infants despite prior administration of antigenic inactivated vaccineAm."/>
  <result pre="Top. Microbiol. Immunol.372201333824362682 76FearnsR.Increased expression of the N protein of" exact="respiratory" post="syncytial virus stimulates minigenome replication but does not alter"/>
  <result pre="balance between the synthesis of mRNA and antigenomeVirology23619971882019299631 77LiuzziM.Inhibitors of" exact="respiratory" post="syncytial virus replication target cotranscriptional mRNA guanylylation by viral"/>
  <result pre="of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by" exact="viral" post="RNA-dependent RNA polymeraseJ. Virol.792005131051311516189012 78MalykhinaO.A respiratory syncytial virus replicon"/>
  <result pre="cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymeraseJ. Virol.792005131051311516189012 78MalykhinaO.A" exact="respiratory" post="syncytial virus replicon that is noncytotoxic and capable of"/>
  <result pre="capable of long-term foreign gene expressionJ. Virol.8520114792480121389127 79Tiong-YipC.-L.Characterization of a" exact="respiratory" post="syncytial virus L protein inhibitorAntimicrob. Agents Chemother.5820143867387324777090 80NotonS.L.Respiratory syncytial"/>
  <result pre="different polymerase activities at the promoterJ. Virol.8920157786779825995255 81LaganasV.A.Characterization of novel" exact="respiratory" post="syncytial virus inhibitors identified by high throughput screenAntiviral Res.1152015717425542974"/>
  <result pre="(ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human" exact="respiratory" post="syncytial virus infectionJ. Med. Chem.5820151862187825667954 83J&amp;amp;J Takes $900 Million"/>
  <result pre="Takes $900 Million Loss as It Writes off RSV Drug" exact="Acquired" post="in $1.7 Billion Alios Deal. Available at: https://www.biospace.com/article/j-and-j-takes-900-million-loss-as-it-writes-off-rsv-drug-acquired-in-1-7-billion-alios-deal/. 84AdlerJ.L.ZicklR.Winter"/>
  <result pre="of role of noroviruses in sporadic gastroenteritisEmerg. Infect. Dis.1420081224123118680645 86StraubT.M.Human" exact="norovirus infection" post="of caco-2 cells grown as a three-dimensional tissue structureJ."/>
  <result pre="role of noroviruses in sporadic gastroenteritisEmerg. Infect. Dis.1420081224123118680645 86StraubT.M.Human norovirus" exact="infection" post="of caco-2 cells grown as a three-dimensional tissue structureJ."/>
  <result pre="norovirus genome: the variable polypyrimidine tract plays a role in" exact="viral" post="virulenceJ. Virol.8420102859287020053745 90SimmondsP.Bioinformatic and functional analysis of RNA secondary"/>
  <result pre="in viral virulenceJ. Virol.8420102859287020053745 90SimmondsP.Bioinformatic and functional analysis of RNA" exact="secondary" post="structure elements among different genera of human and animal"/>
  <result pre="and Ebola virus by using artificial replication systemsJ. Virol.731999233323429971816 99TaoW.Novel" exact="stable" post="Ebola virus minigenome replicon reveals remarkable stability of the"/>
  <result pre="stable Ebola virus minigenome replicon reveals remarkable stability of the" exact="viral" post="genomeJ. Virol.91201710.1128/JVI.01316-17 100WattA.A novel life cycle modeling system for"/>
  <result pre="identification of therapeutic targetsJ. Proteome Res.1520164290430327786485 105HayasakaD.Sub-genomic replicons of Tick-borne" exact="encephalitis" post="virusArch. Virol.14920041245125615168210 106LiS.-H.Development and characterization of the replicon system"/>
  <result pre="virusArch. Virol.14920041245125615168210 106LiS.-H.Development and characterization of the replicon system of" exact="Japanese encephalitis" post="live vaccine virus SA14-14-2Virol. J.1020136423442449 107BehrensS.E.Characterization of an autonomous"/>
  <result pre="Virol.14920041245125615168210 106LiS.-H.Development and characterization of the replicon system of Japanese" exact="encephalitis" post="live vaccine virus SA14-14-2Virol. J.1020136423442449 107BehrensS.E.Characterization of an autonomous"/>
  <result pre="Forest virus repliconBiotechnol. Nat.9199113561361 109AlmazánF.Engineering a replication-competent, propagation-defective Middle East" exact="respiratory" post="syndrome coronavirus as a vaccine candidatemBio42013e006500061324023385 110KortekaasJ.Creation of a"/>
  <result pre="virus repliconBiotechnol. Nat.9199113561361 109AlmazánF.Engineering a replication-competent, propagation-defective Middle East respiratory" exact="syndrome" post="coronavirus as a vaccine candidatemBio42013e006500061324023385 110KortekaasJ.Creation of a nonspreading"/>
  <result pre="syndrome coronavirus as a vaccine candidatemBio42013e006500061324023385 110KortekaasJ.Creation of a nonspreading" exact="Rift Valley fever" post="virusJ. Virol.852011126221263021957302 111BrennanB.Reverse genetics system for severe fever with"/>
  <result pre="fever virusJ. Virol.852011126221263021957302 111BrennanB.Reverse genetics system for severe fever with" exact="thrombocytopenia" post="syndrome virusJ. Virol.8920153026303725552716 112HassM.Replicon system for Lassa virusJ. Virol.782004137931380315564487"/>
  <result pre="virusJ. Virol.852011126221263021957302 111BrennanB.Reverse genetics system for severe fever with thrombocytopenia" exact="syndrome" post="virusJ. Virol.8920153026303725552716 112HassM.Replicon system for Lassa virusJ. Virol.782004137931380315564487 113FreibergA.Establishment"/>
  <result pre="human metapneumovirus, from cloned cDNAMethods Mol. Biol.1602201712513928508218 115KalhoroN.H.A recombinant vesicular" exact="stomatitis" post="virus replicon vaccine protects chickens from highly pathogenic avian"/>
  <result pre="vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic" exact="avian influenza" post="virus (H7N1)Vaccine2720091174118319135116 116PattnaikA.K.Infectious defective interfering particles of VSV from"/>
 </snippets>
</snippetsTree>
